The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Open accessAbstract
High-throughput DNA sequencing significantly contributed to diagnosis and prognostication in patients with myelodysplastic syndromes (MDS). We determined the biological and prognostic significance of genetic aberrations in MDS. In total, 944 patients with various MDS subtypes were screened for known/putative mutations/deletions in 104 genes using targeted deep sequencing and array-based genomic hybridization. In total, 845/944 patients (89.5%) harbored at least one mutation (median, 3 per patient; range, 0-12). Forty-seven genes were significantly mutated with TET2, SF3B1, ASXL1, SRSF2, DNMT3A, and RUNX1 mutated in >10% of cases. Many mutations were associated with higher risk groups and/or blast elevation. Survival was investigated in 875 patients. By univariate analysis, 25/48 genes (resulting from 47 genes tested significantly plus PRPF8) affected survival (P<0.05). The status of 14 genes combined with conventional factors revealed a novel prognostic model ('Model-1') separating patients into four risk groups ('low', 'intermediate', 'high', 'very high risk') with 3-year survival of 95.2, 69.3, 32.8, and 5.3% (P<0.001). Subsequently, a 'gene-only model' ('Model-2') was constructed based on 14 genes also yielding four significant risk groups (P<0.001). Both models were reproducible in the validation cohort (n=175 patients; P<0.001 each). Thus, large-scale genetic and molecular profiling of multiple target genes is invaluable for subclassification and prognostication in MDS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“dysregulated iron metabolism is a hallmark of a large subset of MDS with ringed sideroblasts (MDS-RS), characterized by aberrant iron accumulation in erythroblast mitochondria and accounting for ~30% of all MDS cases (42).”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 gene mutations are detected in approximately 10%-20% of patients with de novo myelodysplastic syndromes (MDS)1-4 or acute myeloid leukemia (AML)5,6 and 30%-40% of patients with therapy-related disease.7”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the context of MDS, eprenetapopt is currently only indicated in ~7% of all MDS cases (42).”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Splicing factor mutations are common in AMl and other blood malignancies and are often mutually exclusive (Haferlach et al. 2014;Papaemmanuil et al. 2016), indicating that cancers harboring such mutations may rely on an intact splicing machinery for survival (lee et al. 2018).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Haferlach et al. 2014
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482
Sequencing technologies – the next generation
Metzker, M. L. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2626 · Cited by 7,066
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,224
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Self-citationDNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Several Tests for Model Specification in the Presence of Alternative Hypotheses
Davidson, R., & MacKinnon, J. G. (1981) · Econometrica · doi:10.2307/1911522 · Cited by 1,747
Flagged first, then by citations
Research works printed but not linked: 1
- Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman J et al. Myelodysplastic syndromes. In: Jaffe ES, Harris N, Stein H, Vardiman J, eds World Health Organization of Tumors, Pathology & Genetics, Tumors of haematopoietic and lymphoid tissues. IARC Press: Lyon, France, 2001; pp 61–73.
Cited by
Sorted by citations
Items 901–999 of 999
Clonal haematopoiesis - a novel entity that modifies pathological processes in elderly
Belotserkovskaya, E., Golotin, V., Uyanik, B., & Demidov, O. N. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01590-z · Cited by 8
Genetic Characteristics of Patients with Young-Onset Myelodysplastic Neoplasms
Kim, H., Yoo, K. H., Jung, C. W., Kim, H., & Kim, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247651 · Cited by 7
Pinheiro, R. F., Goes, J. V. C., Sampaio, L. R., de Oliveira, R. T. G., Soares‐Lima, S. C., Furtado, C. L. M., Borges, D. D. P., Costa, M. B., Monte, C. D. S., Minete, N., et al. (2025) · DNA repair · doi:10.1016/j.dnarep.2024.103803 · Cited by 7
Distinct routes of clonal progression in SF3B1-mutant myelodysplastic syndromes
Sarchi, M., Clough, C. A., Gallì, A., Picone, C., Ferrari, B., Crosse, E. I., Galvis, L. D. B., Fiducioso, C., Aydinyan, N., Creamer, J. P., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014965 · Cited by 8
Valka, J., Veselá, J., Votavová, H., Merkerová, M. D., Hořáková, Z., Campr, V., Březinová, J., Zemanová, Z., Jonasova, A. T., Čermák, J., et al. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12920 · Cited by 7
Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints
Hidalgo‐Lόpez, J. E., Kanagal‐Shamanna, R., Quesada, A. E., Thakral, B., Hu, Z., Mitsuhashi, T., Yabe, M., Garcia‐Manero, G., & Bueso-Ramos, C. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.022 · Cited by 7
Chromosomal analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki
Horai, M., Satoh, S., Matsuo, M., Iwanaga, M., Horio, K., Jo, T., Takasaki, Y., Kawaguchi, Y., Tsushima, H., Yoshida, S., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.15050 · Cited by 7
Advances in diagnosis of mastocytosis and hypereosinophilic syndrome☆
Marić, I., & Sun, X. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.05.005 · Cited by 7
Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes
Kobbe, G., Schroeder, T. A., Rautenberg, C., Kaivers, J., Gattermann, N., Haas, R. R., & Germing, U. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1645004 · Cited by 7
Song, J., Hussaini, M., Qin, D., Zhang, X., Shao, H., Zhang, L., Gajzer, D. C., Basra, P., Moscinski, L. C., & Zhang, H. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa016 · Cited by 8
The Evolving Landscape of Myelodysplastic Syndrome Prognostication
Shreve, J. T., & Nazha, A. (2020) · Clinical Hematology International · doi:10.2991/chi.d.200408.001 · Cited by 7
Circular RNAs in Hematopoiesis with a Focus on Acute Myeloid Leukemia and Myelodysplastic Syndrome
Merkerová, M. D., Krejčík, Z., Szikszai, K., & Kundrát, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21175972 · Cited by 7
Stem cell concepts in myelodysplastic syndromes: lessons and challenges
Woll, P. S., & Jacobsen, S. E. W. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13283 · Cited by 7
SYSTEMIC MASTOCYTOSIS: MOLECULAR LANDSCAPE AND IMPLICATIONS FOR TREATMENT
Monaldi, C., Santis, S. D., Mancini, M., Bruno, S., Cavo, M., & Soverini, S. (2021) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2021.046 · Cited by 9
Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine
Chanias, I., Stojkov, K., Stehle, G., Daskalakis, M., Simeunovic, H., Njue, L. M., Schnegg-Kaufmann, A. S., Porret, N. A., Allam, R., Rao, T. N., et al. (2021) · Cancers · doi:10.3390/cancers13133296 · Cited by 7
Self-citationKataoka, N., Matsumoto, E., & Masaki, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157789 · Cited by 9
Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance
Han, W., Zhou, F., Wang, Z., Hua, H., Qin, W., Jia, Z., Cai, X., Chen, M., Liu, J., Chao, H., et al. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03210-x · Cited by 7
Bioinformatics analysis of high frequency mutations in myelodysplastic syndrome-related patients
Wu, K., Nie, B., Li, L., Yang, X. L., Yang, J., He, Z., Li, Y., Cheng, S., Shi, M., & Zeng, Y. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4094 · Cited by 6
Zhang, B., Ding, Z., Li, L., Xie, L.-K., Fan, Y., & Xu, Y. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009861 · Cited by 8
Wang, C., & Sallman, D. A. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000569 · Cited by 8
A predictive model for bone marrow disease in cytopenia based on noninvasive procedures
Træden, D., Tulstrup, M., Cowland, J. B., Sjø, L. D., Bøgsted, M., Grønbæk, K., Andersen, M. K., & Hansen, J. W. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006649 · Cited by 7
Weinstein, R. N., Bishop, K. S., Broadbridge, E., Yu, K., Carrington, B., ELKAHLOUN, A. G., Zhen, T., Pei, W., Burgess, S. M., Liu, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810668 · Cited by 7
Delio, M., Bryke, C. R., Mendez, L., Joseph, L. J., & Jassim, S. H. (2023) · Hematology Reports · doi:10.3390/hematolrep15010008 · Cited by 7
Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication
Maggioni, G., & Porta, M. G. D. (2022) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000752 · Cited by 7
Sabile, J. M. G., Kaempf, A. J., Tomic, K., Manu, G., Swords, R. T., & Migdady, Y. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2232491 · Cited by 7
Monitoring molecular changes in the management of myelodysplastic syndromes
Duployez, N., & Preudhomme, C. (2024) · British Journal of Haematology · doi:10.1111/bjh.19614 · Cited by 7
Life after hypomethylating agents in myelodysplastic syndrome
Santini, V. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000117 · Cited by 7
Kitamura, T., Watanabe‐Okochi, N., Enomoto, Y., Nakahara, F., Oki, T., Komeno, Y., Kato, N., Doki, N., Uchida, T., Kagiyama, Y., et al. (2015) · The Journal of Biochemistry · doi:10.1093/jb/mvv114 · Cited by 7
Multimodality Technologies in the Assessment of Hematolymphoid Neoplasms
Li, S., Jaye, D. L., Bradley, K. T., Zhang, L., Saxe, D., Deeb, G., Hill, C. E., & Mann, K. P. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0260-sa · Cited by 7
Ye, L., Ren, Y., Zhou, X., Mei, C., Ma, L., Ye, X., Wei, J., Xu, W., Meng, H., Qian, W., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2331-0 · Cited by 7
Janusz, K., Rey, M. D., Abáigar, M., Collado, R., Ivars, D., Hernández‐Sánchez, M., Valiente, A., Robledo, C., Benito, R., Díez‐Campelo, M., et al. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.01.031 · Cited by 7
Self-citationBräuninger, A., Blau, W., Kunze, K., Desch, A.-K., Brobeil, A., Tur, M. K., Etschmann, B., Günther, U., Körholz, D., Schliesser, G., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.01.006 · Cited by 6
ASXL1 is a molecular predictor in idiopathic cytopenia of undetermined significance
Shin, D., Park, J. K., Kim, S., Im, K., Kim, J., Kim, S. Y., Hwang, S. M., Yoon, S., & Lee, D. S. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1492129 · Cited by 7
Behrens, Y. L., Thomay, K., Hagedorn, M., Ebersold, J., Schmidt, G., Lentes, J., Davenport, C., Schlegelberger, B., & Göhring, G. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22665 · Cited by 7
Bewersdorf, J. P., & Zeidan, A. M. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1761968 · Cited by 7
Carraway, H. E., & LaFramboise, T. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101191 · Cited by 7
Jung, H. A., Jung, C. W., & Jang, J. H. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.385 · Cited by 7
Reilly, B. M., Luger, T., Park, S., Lio, C. J., González‐Avalos, E., Wheeler, E. C., Lee, M., Williamson, L. M., Tanaka, T. N., Diep, D. H., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0453 · Cited by 7
Hughes, C., Gallipoli, P., & Agarwal, R. (2021) · Pathology · doi:10.1016/j.pathol.2021.01.005 · Cited by 9
Jorge, M. L., Madueño, J. H., & Martínez-Martínez, D. (2013) · AECA: Revista de la Asociación Española de Contabilidad y Administración de Empresas · Cited by 7
Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench
Tu, S., Singh, S. R. K., Arnaoutakis, K., Malapati, S. J., Bhatti, S. A., Joon, A. Y., Atiq, O. T., & Pisters, L. L. (2022) · Cancers · doi:10.3390/cancers14143345 · Cited by 7
Imprinted genes in myeloid lineage commitment in normal and malignant hematopoiesis
Benetatos, L., & Vartholomatos, G. (2015) · Leukemia · doi:10.1038/leu.2015.47 · Cited by 7
Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets
Taborda, C., Zeidan, A. M., & Mendez, L. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1419323 · Cited by 6
Alternative splicing regulation and its therapeutic potential in bladder cancer
Li, L., Jin, T., Hu, L., & Ding, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1402350 · Cited by 6
Cohesin mutations and chromatin changes in cancer
Swett, A. D., & Tóthová, Z. (2025) · International Journal of Cancer · doi:10.1002/ijc.35378 · Cited by 7
Is the bone marrow microenvironment the hidden catalyst in malignant haematopoiesis?
Mian, S. A., Ngo, S. D., & Bonnet, D. A. (2025) · Leukemia · doi:10.1038/s41375-025-02630-6 · Cited by 8
Hu, J., Xu, J., Tian, T., Xie, J., Fan, L., Zhu, G., Xia, T., Chen, X., Tan, Y., Chen, X., et al. (2018) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2018.11.002 · Cited by 6
Genomic Stratification of Hematological Malignancies
Robbe, P., & Schuh, A. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000902 · Cited by 6
Correlation analysis between auto-immunological and mutational profiles in myelodysplastic syndromes
Cristiano, A., Belardi, R., Hajrullaj, H., Fabiani, E., Falconi, G., Galossi, E., Bernardini, S., Voso, M. T., & Nuccetelli, M. (2023) · Inflammation Research · doi:10.1007/s00011-023-01773-5 · Cited by 7
Guarnera, L., Fabiani, E., Attrotto, C., Hajrullaj, H., Cristiano, A., Latagliata, R., Fenu, S., Buccisano, F., Consalvo, M. A. I., Conti, C., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05384-2 · Cited by 7
Comprehensive genomic profiling reveals molecular subsets of ASXL1 -mutated myeloid neoplasms
Johnson, S. M., Haberberger, J., Galeotti, J., Ramkissoon, L. A., Coombs, C. C., Richardson, D. R., Foster, M. C., Duncan, D. L., Montgomery, N. D., Ferguson, N. L., et al. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2277672 · Cited by 7
Lee, C., Kim, H. N., Kwon, J. A., Hwang, J., Park, J.-Y., Shin, O. S., Yoon, S., & Yoon, J. H. (2023) · Cancers · doi:10.3390/cancers15215289 · Cited by 6
Bidikian, A., Bewersdorf, J. P., Shallis, R. M., Getz, T. M., Stempel, J. M., Kewan, T. Z., Stahl, M. F., & Zeidan, A. M. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2414071 · Cited by 6
Duncavage, E. J., OʼBrien, J., Vij, K. R., Miller, C. A., Chang, G. S., Shao, J., Jacoby, M. A., Heath, S. C., Janke, M. R., Elliott, K., et al. (2016) · Leukemia · doi:10.1038/leu.2016.247 · Cited by 6
Molecular Testing in Patients with Suspected Myelodysplastic Syndromes
Moyo, T. K., & Savona, M. R. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0356-8 · Cited by 7
Gao, T., Yu, C., Xia, S., Liang, T., Gu, X., & Liu, Z. (2020) · Therapeutic Advances in Hematology · doi:10.1177/2040620720927105 · Cited by 16
Pathophysiology of Myelodysplastic Syndromes
Fontenay, M., Farhat, B., & Boussaid, I. (2021) · Hemato · doi:10.3390/hemato2030030 · Cited by 6
Reducing cytogenetic testing in the era of next generation sequencing: Are we choosing wisely?
Kawata, E., Hedley, B. D., Chin-Yee, B. H., Xenocostas, A., Lazo‐Langner, A., Hsia, C. C., Howson‐Jan, K., Yang, P., Levy, M. A., Santos, S., et al. (2021) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13747 · Cited by 6
Gao, X., Fan, S., & Zhang, X. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106906 · Cited by 6
Clinical manifestations of clonal hematopoiesis: What has SF3B1-mutant MDS taught us?
Todisco, G., Moura, P. L., & Hellström‐Lindberg, E. (2022) · Seminars in Hematology · doi:10.1053/j.seminhematol.2022.08.002 · Cited by 5
Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS
Buck, M. C., Bast, L., Hecker, J. S., Rivière, J., Rothenberg‐Thurley, M., Vogel, L., Wang, D., Andrä, I., Theis, F. J., Bassermann, F. C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107328 · Cited by 6
Xue, Y., Xia, X., Liu, X., Zheng, Y., Gu, H., & Wang, X. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2902086 · Cited by 7
Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms
Patel, B. J., Hirsch, C. M., Clemente, M. J., Sekeres, M. A., Makishima, H., & Maciejewski, J. P. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1747-7 · Cited by 6
The iron fist: malaria and hepcidin
Mohandas, N., & Hillyer, C. D. (2014) · Blood · doi:10.1182/blood-2014-04-562223 · Cited by 6
Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?
Zeidan, A. M., Prébet, T., Aldin, E. S., & Gore, S. D. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.891437 · Cited by 6
Mishra, A., & Anasetti, C. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.02.023 · Cited by 6
Cedena, M., Rapado, I., Santos‐Lozano, A., Ayala, R. M., Onecha, E., Abáigar, M., Such, E., Ramos, F., Cervera, J., Sanz, G. F., et al. (2017) · Leukemia Research · doi:10.1016/s0145-2126(17)30210-2 · Cited by 6
Stengel, A., Kern, W., Meggendorfer, M., Haferlach, T., & Haferlach, C. (2017) · Leukemia · doi:10.1038/leu.2017.180 · Cited by 6
Self-citationShallis, R. M., Xu, M. L., Podoltsev, N. A., Curtis, S. A., Considine, B., Khanna, S. R., Siddon, A. J., & Zeidan, A. M. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3474-7 · Cited by 6
Kimura, S., Hasegawa, D., Yoshimoto, Y., Seki, M., Daida, A., Sekiguchi, M., Hirabayashi, S., Hosoya, Y., Kobayashi, M., Miyano, S., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.9985 · Cited by 5
Self-citationYe, L., Ren, Y., Zhou, X., Mei, C., Xu, W., Ma, L., Luo, Y., Hu, C., Ye, X., Wei, J., et al. (2019) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2019.03.010 · Cited by 6
Novel therapies in myelodysplastic syndromes
Swoboda, D. M., Gesiotto, Q., & Sallman, D. A. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000562 · Cited by 7
Xiong, B., Xue, M., Yu, Y., Wu, S., & Zuo, X. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.01.005 · Cited by 6
Myelodysplastic syndromes in a pediatric patient with Cri du Chat syndrome with a ring chromosome 5
Nozawa, A., Ozeki, M., Yasue, S., Endo, S., Kadowaki, T., Ohnishi, H., Muramatsu, H., Hama, A., Takahashi, Y., Kojima, S., et al. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02909-7 · Cited by 6
Myelodysplastic syndromes and overlap syndromes
Chang, Y. H. (2021) · Blood Research · doi:10.5045/br.2021.2021010 · Cited by 8
Prognosis in Myelodysplastic Syndromes: The Clinical Challenge of Genomic Integration
Chen‐Liang, T. H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102052 · Cited by 6
Ibrar, W., Zhang, W., Cox, J. L., Cushman‐Vokoun, A. M., Fu, K., Greiner, T. C., & Ji, Y. (2021) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13659 · Cited by 6
O-GlcNAcylation: Implications in normal and malignant hematopoiesis
Nakajima, H., & Murakami, K. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.07.003 · Cited by 6
Mouse Models of Frequently Mutated Genes in Acute Myeloid Leukemia
Mohanty, S., & Heuser, M. (2021) · Cancers · doi:10.3390/cancers13246192 · Cited by 6
He, R. Q., Oliveira, J. L., Hoyer, J. D., & Viswanatha, D. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-47913-4.00024-0 · Cited by 6
Nn, M., Latypova, M. V., Shakirova, A. I., Gindina, T., Kanunnikov, M. M., Tcvetkov, N., Barkhatov, I., Bondarenko, S. N., Vladovskaya, M. D., & Морозова, Е. В. (2022) · Clinical oncohematology · doi:10.21320/2500-2139-2022-15-1-62-68 · Cited by 6
Tan, J., Chow, Y. P., Abidin, N. Z., Chang, K. M., Selvaratnam, V., Tumian, N. R., Poh, Y. M., Veerakumarasivam, A., Laffan, M., & Wong, C. L. (2022) · BMC Medical Genomics · doi:10.1186/s12920-021-01145-0 · Cited by 7
Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations
Urrutia, S., Li, Z., Almanza, E., Bataller, Á., Kanagal‐Shamanna, R., Senapati, J., Sasaki, K., Chien, K. S., Bravo, G. M., Dinardo, C. D., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01899-9 · Cited by 6
The Etiology of Acute Leukemia
Nichol, J. N., Assouline, S. E., & Miller, W. H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_14 · Cited by 6
Ramos, F., Robledo, C., Pereira, A., Pedro, C., Benito, R., de Paz, R., Rey, M. D., Insunza, A., Tormo, M., Díez‐Campelo, M., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24813 · Cited by 6
Tipping Clonal Hematopoiesis into Transformation
Karlsson, S. (2018) · New England Journal of Medicine · doi:10.1056/nejmcibr1803641 · Cited by 6
Hj, H., Zx, S., Li, B., Tj, Q., Zf, X., Hl, Z., Lw, F., Nb, H., Lj, P., Sq, Q., et al. (2019) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2019.03.010 · Cited by 6
Pine, A. B., Chokr, N., Stahl, M. F., Steensma, D. P., Sekeres, M. A., Litzow, M. R., Luger, S. M., Stone, R. M., Greenberg, P. L., Bejar, R. L., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1723013 · Cited by 6
Do somatic mutations in de novo MDS predict for response to treatment?
Schroeder, M. A., & Dezern, A. E. (2015) · Hematology · doi:10.1182/asheducation-2015.1.317 · Cited by 6
Mouse Models of Myeloid MalignanciesPreprint
Basheer, F., & Vassiliou, G. S. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a035535 · Cited by 6
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances
Thalambedu, N., Lal, B. M., Harbaugh, B., Alapat, D. V., Gaddam, M., Sanchez, C. G., Kumaran, M. S., & Varma, A. (2025) · Cancers · doi:10.3390/cancers17030508 · Cited by 5
Munteanu, R. A., Gulei, D., Moldovan, C. S., Azzoni, E., Belver, L., Feder, R., Pîrv, S., Buzoianu, A. D., Einsele, H., Mittelman, M., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07861-0 · Cited by 5
Symeonidis, A. S., Chroni, A., Dereki, I., Chartoumpekis, D. V., & Sgourou, A. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090758 · Cited by 5
Chonabayashi, K., Iwasaki, M., Kanda, J., Takamori, H., Yoda, A., Kawata, T., Mizuta, S., Sakurada, M., Kondo, T., Hiramoto, N., et al. (2026) · Leukemia · doi:10.1038/s41375-025-02848-4 · Cited by 7
Self-citationGenomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort
Kanamori, T., Sanada, M., Ri, M., Ueno, H., Nishijima, D., Yasuda, T., Tachita, T., Narita, T., Kusumoto, S., Inagaki, A., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16720 · Cited by 5
Self-citationMyelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications
Bruzzese, A., Martino, E. A., Mendicino, F., Lucia, E., Olivito, V., Capodanno, I., Neri, A., Morabito, F., Vigna, E., & Gentile, M. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14181 · Cited by 6
Orsmark‐Pietras, C., Lyander, A., Ladenvall, C., Hallström, B. M., Staffas, A., Awier, H. N., Krstic, A., Baliakas, P., Barbany, G., Brunhoff, C., et al. (2024) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23257 · Cited by 5
Mazzeo, P., Ganster, C., Wiedenhoeft, J., Shirneshan, K., Rittscher, K., Brzuszkiewicz, E., Steinemann, D., Schieck, M., Müller‐Thomas, C., Treiber, H., et al. (2024) · HemaSphere · doi:10.1002/hem3.70014 · Cited by 6
Bülbül, H., Kaya, Ö. Ö., Karadağ, F. K., Olgun, A., Demirci, Z., & Ceylan, C. (2024) · Medicine · doi:10.1097/md.0000000000039909 · Cited by 5
Metadata
- Authors
- Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., Yoshida, K., Roller, A., Nadarajah, N., Shiraishi, Y., Shiozawa, Y., Chiba, K., Tanaka, H., Koeffler, H. P., Klein, H.-U., Dugas, M., Aburatani, H., Kohlmann, A., Miyano, S., Haferlach, C., Kern, W., & Ogawa, S.
- Affiliations
- Munich Leukemia Laboratory (Germany) (DE)
- Kyoto University (JP)
- The University of Tokyo (JP)
- Research Center for Advanced Science and Technology, The University of Tokyo (JP)
- Institute of Medical Science, The University of Tokyo (JP)
- Cedars-Sinai Medical Center (US)
- University of Münster (DE)
- Corresponding author
- Haferlach, T
- Ogawa, S
- ORCID
- Venue
- Leukemia
- Published
- 2013-11-13
- Volume
- 28
- Issue
- 2
- Pages
- 241-247
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC3918868
- OpenAlex
- W2026134786
- Cited by
- 1,532
- References
- 32
- Citations by year
- 2026: 56 · 2025: 85 · 2024: 102 · 2023: 132 · 2022: 133 · 2021: 177 · 2020: 167 · 2019: 134 · 2018: 117 · 2017: 136 · 2016: 126 · 2015: 105 · 2014: 56 · 2013: 3
- FWCI
- 69.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- Leukemia (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- Funders
- U.S. Public Health Service (08C46598A)
- Japan Society for the Promotion of Science (24390242, 24659458, 21790907, 25670446, 24221011, 23249052)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- myelodysplastic syndrome, somatic mutations, prognostic model, risk stratification, TET2, SF3B1, ASXL1, SRSF2, DNMT3A, RUNX1, PRPF8, survival
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Gene Frequency, Genetic Markers, Humans, Male, Middle Aged, Mutation, Myelodysplastic Syndromes, Prognosis, Proportional Hazards Models, Polymorphism, Single Nucleotide, Young Adult, Genetic Association Studies, High-Throughput Nucleotide Sequencing, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
